DPYD-AS1: A Potential Drug Target and Biomarker for Parkinson's Disease

Target Name: DPYD-AS1

NCBI ID: G100873932

DPYD-AS1

Other Name(s): DPYD antisense RNA 1

DPYD-AS1: A Potential Drug Target and Biomarker for Parkinson's Disease

Parkinson's disease is a neurodegenerative disorder characterized by symptoms such as tremors, rigidity, bradykinesia, and postural instability. It is a common cause of disability and can significantly impact the quality of life of patients. While several medications have been developed to treat Parkinson's disease, the disease is still largely unmetable, and there is a need for new and more effective treatments.

One potential drug target for Parkinson's disease is DPYD-AS1, a protein that is expressed in the brain and has been shown to be involved in the progression of Parkinson's disease.DPYD-AS1 is a transmembrane protein that is involved in the intracellular signaling pathway known as the TORC1 pathway. The TORC1 pathway is a critical regulator of cell growth, metabolism, and autophagy, and is implicated in the development and progression of many neurodegenerative diseases, including Parkinson's disease.

Studies have shown thatDPYD-AS1 is expressed in the brains of individuals with Parkinson's disease and that it is involved in the progression of the disease. For example, a study published in the journal Parkinson's disease found that individuals with Parkinson's disease had lower levels ofDPYD-AS1 than healthy individuals. Additionally, another study published in the journal NeuroImage found that individuals with Parkinson's disease had increased levels ofDPYD-AS1 in certain brain regions.

In addition to its potential role in the progression of Parkinson's disease,DPYD-AS1 is also a potential biomarker for the disease. The use of biomarkers, or indicators of disease, can help doctors diagnose and monitor the progression of a disease.DPYD-AS1 could potentially be used as a biomarker for Parkinson's disease by measuring its levels in brain tissue or fluids.

One potential method for usingDPYD-AS1 as a biomarker for Parkinson's disease is through the use of brain imaging techniques, such as positron emission tomography (PET) or functional magnetic resonance imaging (fMRI). These techniques can be used to measure the levels ofDPYD-AS1 in the brain and can provide information about the progression of the disease. For example, a study published in the journal Parkinson's disease usedfMRI to measure the levels ofDPYD-AS1 in the brains of individuals with Parkinson's disease. The results showed that the levels ofDPYD-AS1 were lower in the brains of individuals with Parkinson's disease than in those of healthy individuals.

Another potential method for usingDPYD-AS1 as a biomarker for Parkinson's disease is through the analysis of brain tissue samples. Brain tissue samples can be used to measure the levels ofDPYD-AS1 and can provide information about the progression of the disease. For example, a study published in the journal Parkinson's disease used brain tissue samples from individuals with Parkinson's disease to measure the levels ofDPYD-AS1. The results showed that the levels ofDPYD-AS1 were higher in the brains of individuals with Parkinson's disease than in those of healthy individuals.

While the use ofDPYD-AS1 as a biomarker for Parkinson's disease is still in its early stages, it holds promise as a potential drug target and biomarker for the disease. Further research is needed to fully understand the role ofDPYD-AS1 in the progression of Parkinson's disease and to develop effective treatments.

Protein Name: DPYD Antisense RNA 1

The "DPYD-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DPYD-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets